Developing new agents for the treatment of childhood cancer

Area of Science:

• Oncology
• Pediatric Oncology
• Drug Development

Background:

• Developing new cancer drugs for children faces unique hurdles, often leading to delayed pediatric clinical trials compared to adult studies.
• While numerous cancer treatment entities are in development, few specifically target childhood malignancies, necessitating a strategic approach to pediatric drug prioritization.
• The disparity in drug development for adult versus pediatric cancers highlights a critical need for specialized evaluation pathways.

Purpose of the Study:

• To outline the molecular characteristics of pediatric cancers that can guide the selection of rational or molecularly targeted treatments.
• To present the National Cancer Institute's Pediatric Preclinical Testing Program (PPTP) as a framework for prioritizing agents for pediatric cancer clinical evaluation.

Main Methods:

• Review of existing literature on the molecular landscape of childhood cancers.
• Description of the National Cancer Institute's Pediatric Preclinical Testing Program (PPTP) methodology and objectives.

Main Results:

• Identification of key molecular features in pediatric malignancies that can inform targeted therapy selection.
• The PPTP framework provides a systematic approach to identifying promising drug candidates for pediatric cancer.

Conclusions:

• Understanding the molecular basis of childhood cancers is crucial for rational drug development and targeted treatment strategies.
• The Pediatric Preclinical Testing Program (PPTP) offers a vital initiative to accelerate the evaluation and prioritization of novel cancer agents for pediatric patients.